AFFiRiS granted new patent in China for treating Parkinson's disease
- Written by Reporters
Patent adds to company's robust portfolio covering clinical stage lead development candidate PD01
VIENNA, AUSTRIA - EQS Newswire - March 3, 2020 - AFFiRiS, a clinical-stage biotechnology company developing novel disease-modifying specific active immunotherapies (SAITs) for patients with neurodegenerative diseases, today announces the...
Read more: AFFiRiS granted new patent in China for treating Parkinson's disease

